Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
Clinical trial NCT04231448 · COMPLETED
Trial details
- NCT number
- NCT04231448
- Sponsor
- Chipscreen Biosciences, Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-21
- Primary completion
- 2023-01-10
- Enrollment
- 423
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.